Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease
暂无分享,去创建一个
E. Clappier | C. Preudhomme | P. Fenaux | A. Toubert | M. Espéli | M. Sébert | L. Adès | R. Itzykson | N. Dulphy | A. Mékinian | K. Balabanian | O. Fain | K. Benlagha | Maxime Boy | A. Marceau-Renaut | L. Benajiba | Lin-Pierre Zhao | C. Azoulay | Ludivine Amable | Jihène Klibi | M. Boy
[1] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[2] C. Deswarte,et al. Clonal haematopoiesis is increased in early onset in systemic sclerosis. , 2020, Rheumatology.
[3] Javier Martín,et al. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome , 2019, The Korean journal of internal medicine.
[4] A. List,et al. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. , 2019, Blood.
[5] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[6] O. Decaux,et al. Efficacy of Azacitidine in Autoimmune and Inflammatory Disorders associated with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Running title : Azacitidine in autoimmune disorders associated with MDS / CMML , 2018 .
[7] S. Inoue,et al. Roles of IDH1/2 and TET2 mutations in myeloid disorders , 2016, International Journal of Hematology.
[8] Harri Lähdesmäki,et al. Control of Foxp3 stability through modulation of TET activity , 2016, The Journal of experimental medicine.
[9] J. Piette,et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.
[10] P. Fenaux,et al. Myelodysplastic syndromes , 2014, The Lancet.
[11] R. Tibshirani,et al. Automated identification of stratifying signatures in cellular subpopulations , 2014, Proceedings of the National Academy of Sciences.
[12] P. Fenaux,et al. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? , 2013, Best practice & research. Clinical haematology.
[13] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[14] B. Quesnel,et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias , 2011, Leukemia.
[15] G. Mufti,et al. IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome , 2009, British journal of haematology.
[16] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.